Press Release

Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.8%Reaction day

₹531.75

prior close

₹531.70

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%-2.4% vs market

Pharmaceuticals peers, median of 160sector-0.1%-2.6% vs sector

On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 2.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.9

10m

-2.3

15m

-2.5

30m

-1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.8-0.4-2.4-0.1-2.6

Next day

-3.3-1.7-1.6-0.9-2.5

-2.2-1.3-1.0-0.2-2.0

-3.6-0.7-2.9+0.3-3.9

-1.6+0.4-2.0+1.1-2.6

-2.1+0.5-2.5+0.2-2.2

+0.1+2.8-2.7+1.0-0.9

15d

+2.1+1.2+0.9-0.3+2.4

+16.4+5.3+11.1+1.5+14.9

+30.2+9.9+20.3+7.7+22.5

+39.7+13.1+26.6+7.6+32.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Akums Drugs reported Q4 FY26 operating revenue of ₹1,158 crore, up 9.7% YoY, with Adj EBITDA of ₹152 crore (up 61.6% YoY) and Adj PAT of ₹83 crore (up 135% YoY). Full-year FY26 revenue stood at ₹4,359 crore (5.9% growth), with Adj EBITDA at ₹522 crore (13.3% growth) and Adj PAT at ₹276 crore (27.3% growth). EBITDA margin improved to 13.1% in Q4 from 8.9% YoY. The CDMO segment was the key growth driver with revenue of ₹952 crore and 54.9% EBITDA growth. The API business continued to face pricing pressure with operating loss of ₹12 crore in Q4. Board recommended dividend of ₹1 per share plus special dividend of ₹2 per share.

Likely market impact

Strong profitability improvement with PAT growth of 27.3% and EBITDA margin expansion signals operational efficiency gains. The special dividend and CDMO business momentum are positive signals for investors, though slow API turnaround remains a concern.